Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 275

The DOI matches its Crossref record; 266 of the 266 references it cites were found in a registry or an index.

Colorectal liver metastases: Current management and future perspectives

Open access
Martin, Jack, Petrillo, Angelica, Smyth, Elizabeth C, Shaida, Nadeem, Khwaja, Samir, Cheow, HK, Duckworth, Adam, Heister, Paula, Praseedom, Raaj, Jah, Asif, Balakrishnan, Anita, Harper, Simon, Liau, Siong, Kosmoliaptsis, Vasilis, Huguet, Emmanuel·2020·World Journal of Clinical Oncology

Abstract

The liver is the commonest site of metastatic disease for patients with colorectal cancer, with at least 25% developing colorectal liver metastases (CRLM) during the course of their illness. The management of CRLM has evolved into a complex field requiring input from experienced members of a multi-disciplinary team involving radiology (cross sectional, nuclear medicine and interventional), Oncology, Liver surgery, Colorectal surgery, and Histopathology. Patient management is based on assessment of sophisticated clinical, radiological and biomarker information. Despite incomplete evidence in this very heterogeneous patient group, maximising resection of CRLM using all available techniques remains a key objective and provides the best chance of long-term survival and cure. To this end, liver resection is maximised by the use of downsizing chemotherapy, optimisation of liver remnant by portal vein embolization, associating liver partition and portal vein ligation for staged hepatectomy, and combining resection with ablation, in the context of improvements in the functional assessment of the future remnant liver. Liver resection may safely be carried out laparoscopically or open, and synchronously with, or before, colorectal surgery in selected patients. For unresectable patients, treatment options including systemic chemotherapy, targeted biological agents, intra-arterial infusion or bead delivered chemotherapy, tumour ablation, stereotactic radiotherapy, and selective internal radiotherapy contribute to improve survival and may convert initially unresectable patients to operability. Currently evolving areas include biomarker characterisation of tumours, the development of novel systemic agents targeting specific oncogenic pathways, and the potential re-emergence of radical surgical options such as liver transplantation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.5306/wjco.v11.i10.761

Cites

266 of 266 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 266 references

Cited by

See all 275

Metadata

Authors
Martin, J., Petrillo, A., Smyth, E. C., Shaida, N., Khwaja, S., Cheow, H., Duckworth, A., Heister, P., Praseedom, R., Jah, A., Balakrishnan, A., Harper, S., Liau, S., Kosmoliaptsis, V., & Huguet, E.
Venue
World Journal of Clinical Oncology
Published
2020-10-24
Volume
11
Issue
10
Pages
761-808
ISSN
2218-4333 (ISSN-L)
OpenAlex
W3094558370
Cited by
275
References
266
FWCI
7.70
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Colorectal liver metastases: Current management and future perspectives. https://app.cochat.ai/papers/10.5306/wjco.v11.i10.761
The paper
Martin, J., Petrillo, A., Smyth, E. C., Shaida, N., Khwaja, S., Cheow, H., Duckworth, A., Heister, P., Praseedom, R., Jah, A., Balakrishnan, A., Harper, S., Liau, S., Kosmoliaptsis, V., & Huguet, E. (2020). Colorectal liver metastases: Current management and future perspectives. World Journal of Clinical Oncology. https://doi.org/10.5306/wjco.v11.i10.761

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.